Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 328 Fallopian Tube Neoplasms 153 Carcinoma, Ovarian Epithelial 115 Endometrial Neoplasms 95 Uterine Cervical Neoplasms 80 Neoplasms 28 Breast Neoplasms 27 Peritoneal Neoplasms 24 Brenner Tumor 24 Carcinoma, Non-Small-Cell Lung 21 Stomach Neoplasms 18 Recurrence 17 Neoplasm Metastasis 14 Uterine Neoplasms 13 Testicular Neoplasms 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 11 Colorectal Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 10 Lung Neoplasms 10 Melanoma 9 Testicular Germ Cell Tumor 8 Central Nervous System Neoplasms 8 Urinary Bladder Neoplasms 7 Triple Negative Breast Neoplasms 7 Esophageal Neoplasms 7 Carcinoma 7 Prostatic Neoplasms 6 Pancreatic Neoplasms 6 Neurotoxicity Syndromes 6 Carcinosarcoma 6

Interventions

Saline Solution 3 Carboplatin 2 Bevacizumab 2 talazoparib 1 stenoparib 1 senaparib 1 sargramostim 1 olaparib 1 niraparib 1 liposomal doxorubicin 1 Tranexamic Acid 1 Ropivacaine 1 Paclitaxel 1 Observation 1 Neoadjuvant Therapy 1 Hyperthermic Intraperitoneal Chemotherapy 1 Antineoplastic Agents 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Ovarian Cancer × Paclitaxel × Gynecologic × Clear all

NCT05794659 2023-07-20

Cornerstone4

Aston Sci. Inc.

Phase 2 Not yet recruiting

Advanced Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡